Is NCT07797335 recruiting in Los Alamitos, CA?

Yes, NCT07797335 is currently enrolling participants at its Los Alamitos, CA location. This type 2 diabetes clinical trial is accepting qualified participants.

How do I join the type 2 diabetes clinical trial in Los Alamitos?

To join this clinical trial in Los Alamitos, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Los Alamitos clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Type 2 Diabetes Clinical Trial in Los Alamitos, CA: Zenagamtide (Phase 3)

About This Type 2 Diabetes Study in Los Alamitos

This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide, (the treatment being tested) or insulin glargine (a comparator) and which treatment participants get is decided by chance.

Sponsor: Novo Nordisk A/S

Who Can Participate

Inclusion Criteria

Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.

Male or female (sex assigned at birth, inclusive of all gender identities).

Age 45 years or above at the time of signing the informed consent.

Diagnosed with type 2 diabetes (T2D) greater than or equal to (≥) 180 days before screening.

Treatment with 1-3 marketed oral glucose-lowering medications (metformin, glinide, thiazolidinedione, sodium-glucose cotransporter-2 inhibitors (SGLT2i), α-glucosidase inhibitors (AGI), or sulfonylureas (SU) as a single agent or in combination) according to local label. Treatment with oral glucose-lowering medications must be stable (same drug(s), stable daily dose(s)) before screening.

Have HbA1c as determined by central laboratory at screening, if background glucose-lowering medications does not include a SU, or if background glucose-lowering medications includes a SU.

Increased risk of cardiovascular events as evidenced by at least one of the following (a-e):

Prior myocardial infarction (MI)

Documented coronary artery disease defined by at least one of the following: -≥ 50% stenosis of coronary artery on angiography or other imaging modality.

Ischaemia documented by stress test with any imaging modality.

Prior unstable angina with electrocardiogram (ECG) changes.

Prior coronary artery bypass graft or prior percutaneous coronary intervention.

Prior stroke (ischemic or haemorrhagic stroke).

History of chronic kidney disease based on medical records or as judged by the investigator as determined by central laboratory at screening.

Symptomatic peripheral arterial disease (PAD) defined as at least one of the following:

Intermittent claudication with an ankle-brachial index (ABI) \< 0.85 at rest.

Intermittent claudication with a ≥ 50% stenosis in a lower extremity peripheral artery documented by X-ray angiography, magnetic resonance (MR) angiography, computer tomography (CT) angiography or Doppler ultrasound.

Prior revascularisation procedure of a lower extremity peripheral artery.

Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g., trauma or osteomyelitis)

Exclusion Criteria

Myocardial infarction, stroke, transient ischaemic attack or hospitalisation for unstable angina pectoris within 60 days before screening.

Planned coronary, carotid or peripheral artery revascularisation.

Chronic or intermittent haemodialysis or peritoneal dialysis within 90 days before screening. Diabetes- or weight related:

Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria before screening. However, insulin treatment for gestational diabetes is allowed as well as short term insulin treatment for a maximum of 14 consecutive days.

Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), dipeptidyl peptidase 4 (DPP-4) inhibitors or amylin analogues before screening.

Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.

Any episodes of diabetic ketoacidosis before screening.

Uncontrolled thyroid disease as per investigator's discretion.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Alamitos?

Yes, this clinical trial (NCT07797335) has an active research site in Los Alamitos, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Type 2 Diabetes Treatment Options in Los Alamitos, CA

If you're searching for type 2 diabetes treatment options in Los Alamitos, CA, this clinical trial (NCT07797335) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Alamitos research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced type 2 diabetes specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all type 2 diabetes clinical trials near you to find additional studies recruiting in your area.

Type 2 Diabetes Clinical Trial in Los Alamitos, CA

Expert Care in Los Alamitos

IRB Approved

No-Cost Care

Apply for This Los Alamitos Location

Why Participate?

Simple Process